Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

Long-term efficacy and safety of eculizumab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder

Dean Wingerchuk,Achim Berthele,Kazuo Fujihara,Celia Oreja-Guevara,Ho Jin Kim, Michael Levy,Ichiro Nakashima,Jacqueline Palace,Shulian Shang,Marcus Yountz,Larissa Miller,Sean Pittock

JOURNAL OF THE NEUROLOGICAL SCIENCES（2021）

Cited 0|Views7
No score
Abstract
In PREVENT, eculizumab reduced relapse risk in patients with aquaporin-4 immunoglobulin G-positive (AQP4+) NMOSD by 94.2% vs placebo. We present the long-term efficacy and safety data from PREVENT (NCT01892345) and its open-label extension (OLE; NCT02003144). Eculizumab is not reimbursed for neurology indications in Italy as of April 2021.
More
Translated text
Key words
neuromyelitis optica spectrum disorder,eculizumab,long-term,g-positive
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined